ReviewAnnals of surgical oncology2026
ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen bladder cancer recurs after bacillus Calmette-Guérin (BCG) for high-risk non-muscle-invasive disease, after trimodal therapy (TMT), or after other bladder-preserving therapy for muscle-invasive disease, patients face time-sensitive decisions that determine whether cure remains achievable. Treating physicians must guide these choices by balancing oncologic safety with quality of life, comorbidities, and patient preferences.
methodsWe reviewed 2024-2025 guidelines from the American Urological Association/Society of Urologic Oncology (AUA/SUO), National Comprehensive Cancer Network (NCCN), and European Association of Urology (EAU), while incorporating pivotal trials and recent drug approvals. Emphasis was placed on translating recommendations into practical decision-making for clinicians and patients.
resultsFor post-BCG recurrence, early radical cystectomy (RC) offers the highest chance of cure for medically fit patients and is recommended throughout all three guidelines. When surgery is not possible or declined, bladder-sparing therapies, including four recently US Food and Drug Administration (FDA)-approved drugs, can be considered with strict surveillance. In post-TMT recurrence, RC is standard for invasive relapse, with bladder preservation reserved for select noninvasive cases. In both settings, optimal outcomes require timely workup, presentation of all viable options, and coordination of multidisciplinary input with a strong emphasis on close surveillance and follow-up.
conclusionsManagement of bladder cancer recurrence is optimized when therapy aligns with patient goals while safeguarding oncologic outcomes. Regardless of the path chosen, early engagement of a multidisciplinary team and shared decision-making are essential to delivering the best possible care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.